viewSeelos Therapeutics

Seelos Therapeutics receives funding grant from Team Sanfilippo Foundation

The money will fund a Phase 2b/3 study for patients with Sanfilippo syndrome types A and B

Brain graphic
Seelos Therapeutics is a clinical-stage biopharmaceutical company based in New York

Seelos Therapeutics Inc (Nasdaq:SEEL) received a grant from the Team Sanfilippo Foundation to help fund open-label studies of SLS-005, its treatment for the rare neurodegenerative disorder.

The funding will go toward a Phase 2b/3 study will evaluate patients with Sanfilippo syndrome types A and B.

A portion of the grant will also be used for a seperate expanded access study for patients with types C and D as well as patients with types A and B who did not qualify for the original study.

READ: Seelos Therapeutics earns patent approval for its neuromuscular disease drug

“TSF is proud to be able to provide funding towards Seelos' Sanfilippo trial and excited to continue working with their team," TSF President Kathy Buckley said. "Improving the lives of the children and families living with Sanfilippo syndrome continues to be our main focus. We will continue to work aggressively to raise additional funds to accommodate as many children as possible into the expanded access program."

The Team Sanfilippo Foundation is a nonprofit research foundation that funds clinical trials of potential therapies.

Seelos Therapeutics is a clinical-stage biopharmaceutical company based in New York developing therapeutics for patients with central nervous system and other rare disorders.

The company’s share price climbed 4.5% to $2.11 on Monday.

This story was updated to clarify that there are two separate studies, rather than a single encompassing one

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Seelos Therapeutics

Price: 0.94 USD

Market: NASDAQ
Market Cap: $33.37 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company...



Seelos Therapeutics rings the Nasdaq opening bell

Seelos Therapeutics Inc (NASDAQ: SEEL) CEO Dr Raj Mehra caught up with Proactive after the clinical-stage biopharmaceutical rung the Nasdaq Stock Market opening bell in Times Square, New York. Dr. Mehra says since listing on the exchange in January, the small company has achieved an...

on 08/12/2019

2 min read